Literature DB >> 9823334

Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo.

H C Crawford1, L M Matrisian, L Liaw.   

Abstract

Secreted phosphoprotein 1 (spp1), the gene encoding osteopontin (OPN), is expressed in many human carcinomas, although its in vivo functions remain unclear. To delineate the role of OPN during tumor progression, we have subjected OPN null mutant mice to repeated applications of a mutagen/carcinogen to induce cutaneous squamous cell carcinoma. OPN null animals exhibited accelerated tumor growth and progression and had a greater number of metastases per animal compared with wild-type animals. However, metastases in the OPN null animals were significantly smaller than in controls. When injected into nude mice, the growth of OPN null tumor lines and the same lines engineered to reexpress spp1 recapitulated the growth differences observed in the progression study. These differences in tumor growth inversely correlated with the degree of macrophage infiltration. Slower-growing, OPN-producing tumors contained significantly more macrophages, although a higher proportion were mannose receptor positive, a characteristic of differentiated resting macrophages. In vitro, OPN null cell lines displayed decreased survival at clonal density compared with OPN-producing lines, an observation consistent with the smaller metastases of the OPN null mice. Overall, we provide evidence for a model where host-derived OPN acts as a macrophage chemoattractant, whereas tumor-derived OPN is able to inhibit macrophage function and enhances the growth or survival of metastases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9823334

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification.

Authors:  Susan A Steitz; Mei Y Speer; Marc D McKee; Lucy Liaw; Manuela Almeida; Hsueh Yang; Cecilia M Giachelli
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Comparison of osteopontin expression in endometrioid endometrial cancer and ovarian endometrioid cancer.

Authors:  Yasunori Hashiguchi; Hiroshi Tsuda; Christina A Bandera; Sadako Nishimura; Takeshi Inoue; Naoki Kawamura; Ross S Berkowitz; Samuel C Mok
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone.

Authors:  Tajneen Natasha; Misty Kuhn; Owen Kelly; Susan R Rittling
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

4.  Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis.

Authors:  Ioanna Giopanou; Ioannis Lilis; Vassilios Papaleonidopoulos; Theodora Agalioti; Nikolaos I Kanellakis; Nikolitsa Spiropoulou; Magda Spella; Georgios T Stathopoulos
Journal:  Oncoimmunology       Date:  2016-11-18       Impact factor: 8.110

5.  Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway.

Authors:  Xianmin Luo; Megan K Ruhland; Ermira Pazolli; Anne C Lind; Sheila A Stewart
Journal:  Mol Cancer Res       Date:  2011-06-14       Impact factor: 5.852

6.  Functional characterization of OPN in human laryngeal squamous cell carcinoma and its xenograft model in nude mice.

Authors:  Jianqiu Chen; Qi Zhou; Chunsheng Zhu; Minhui Zhu; Yongsheng Tian; Guojun Li; Xiaofeng Tao; Hongliang Zheng
Journal:  Int J Clin Exp Med       Date:  2015-01-15

7.  Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor.

Authors:  Y H Lin; C J Huang; J R Chao; S T Chen; S F Lee; J J Yen; H F Yang-Yen
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

8.  Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis.

Authors:  Yong Li; Liang Li; Jing Ting Wang; Xuan Kan; Jian Guang Lu
Journal:  Med Oncol       Date:  2011-06-26       Impact factor: 3.064

9.  Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma.

Authors:  Jennifer Sullivan; Laurel Blair; Amer Alnajar; Tamer Aziz; Chee Yuan Ng; Galina Chipitsyna; Qiaoke Gong; Agnes Witkiewicz; Georg F Weber; David T Denhardt; Charles J Yeo; Hwyda A Arafat
Journal:  Surgery       Date:  2009-08       Impact factor: 3.982

10.  The role of osteopontin in inflammatory processes.

Authors:  Susan Amanda Lund; Cecilia M Giachelli; Marta Scatena
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.